---
title: "Why MetaVia Stock Is Falling On Thursday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287261586.md"
description: "MetaVia Inc. (NASDAQ: MTVA) shares fell over 10% on Thursday due to profit-taking after a 175% surge earlier in the week. Despite announcing peer-reviewed data supporting its anti-fibrotic drug candidate, vanoglipel, the stock is trading at $2.78, down 3.63%. The company continues to focus on cardiometabolic treatments, but shares remain 55.6% below the 200-day SMA, reflecting a 12-month decline of 73.01%. Key resistance is at $2.85 and support at $2.52."
datetime: "2026-05-21T18:30:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287261586.md)
  - [en](https://longbridge.com/en/news/287261586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287261586.md)
generator: "portal-rs"
---

# Why MetaVia Stock Is Falling On Thursday?

**MetaVia Inc.** (NASDAQ:MTVA) stock is trading lower on Thursday, presenting a sharp reversal from its recent momentum.

## Profit-Taking Halts The Massive Weekly Rally

The primary driver behind Thursday’s decline is widespread profit-taking. MetaVia stock experienced a 175% surge in the week, closing at $2.89 on Wednesday. 

## Peer-Reviewed Research Validates Vanoglipel

On Wednesday, MetaVia published new preclinical research in the journal Biomolecules & Therapeutics. The study, titled “A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells,” demonstrated that GPR119 agonists reduce liver fibrosis and suppress key pathways that develop liver scar tissue.

## CEO Highlights Consistency With Phase 2a Data

The published findings independently validate MetaVia's clinical pipeline. In the announcement, **Hyung Heon Kim**, President and CEO of MetaVia, stated, “In the trial, patients treated with vanoglipel demonstrated statistically significant reductions in ALT levels, and the serum fibrosis marker TIMP1, along with a positive trend in liver fibrosis as measured by VCTE (-10.2% from the baseline vs. +10.1% for placebo) after 16-week treatment.”

## Clinical Pipeline Targets Cardiometabolic Diseases

The Cambridge, Massachusetts-based clinical-stage biotechnology company continues to focus on cardiometabolic treatments. Alongside vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH), MetaVia is also developing DA-1726, a dual agonist targeting obesity. 

## Critical Levels To Watch for MetaVia (MTVA) Stock

From a trend perspective, MTVA is trading 80.8% above the 20-day SMA ($1.44), 83.8% above the 50-day SMA ($1.41), and just 3% above the 100-day SMA ($2.52). 

The bigger picture remains damaged, though, with shares still trading 55.6% below the 200-day SMA ($5.85), which is consistent with the stock's 12-month slide of 73.01%.

Momentum is the key tell right now: RSI is at 80.57.

-   **Key Resistance**: $2.85
-   **Key Support**: $2.52

**MTVA Stock Price Activity:** MetaVia shares were down 3.63% at $2.78 at the time of publication on Thursday, according to Benzinga Pro data.

*Photo Courtesy: TIMS13 on Shutterstock.com*

### Related Stocks

- [MTVA.US](https://longbridge.com/en/quote/MTVA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [MetaVia Advances DA-1726 Obesity Trial to Top Doses](https://longbridge.com/en/news/292215429.md)
- [How Investors Are Reacting To Medtronic (MDT) Cardiac Ablation Surge And Near-Dividend-King Milestone](https://longbridge.com/en/news/296452586.md)
- [CVS Health: Every Community Deserves a Healthier Heart](https://longbridge.com/en/news/296627920.md)
- [Realheart targets February 2028 readiness for first-in-human implant of total artificial heart](https://longbridge.com/en/news/296444895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**